Adn-388 Hot!

ADN-388 (Atezolizumab) has been approved for the treatment of various types of cancer, including:

The timeline for ADN-388's availability depends on its intended applications and regulatory approvals, which are expected to unfold in the coming years. ADN-388

| Feature | ADN‑388 | Conventional Antivirals | |---------|--------|--------------------------| | | Conserved RdRp motif (Motif C) | Virus‑specific proteins (e.g., proteases, entry receptors) | | Spectrum | Broad (≥15 RNA virus families) | Narrow (typically 1–2 related viruses) | | Resistance Barrier | High (multiple simultaneous mutations required) | Low to moderate | | Oral Bioavailability | >80% (fasted) | Variable | | Safety Margin (LD₅₀/ED₅₀) | >10,000× | 100–1,000× | ADN-388 (Atezolizumab) has been approved for the treatment